Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Change in Account Payables: 2016-2024

Historic Change in Account Payables for Viridian Therapeutics, Inc.\DE (VRDN) over the last 9 years, with Dec 2024 value amounting to -$73,000.

  • Viridian Therapeutics, Inc.\DE's Change in Account Payables fell 47.24% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year increase of 72.19%. This contributed to the annual value of -$73,000 for FY2024, which is 99.39% up from last year.
  • According to the latest figures from FY2024, Viridian Therapeutics, Inc.\DE's Change in Account Payables is -$73,000, which was up 99.39% from -$12.0 million recorded in FY2023.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Change in Account Payables peaked at $11.5 million during FY2022, and registered a low of -$12.0 million during FY2023.
  • In the last 3 years, Viridian Therapeutics, Inc.\DE's Change in Account Payables had a median value of -$73,000 in 2024 and averaged -$196,333.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Change in Account Payables skyrocketed by 596.31% in 2022 and then slumped by 204.48% in 2023.
  • Viridian Therapeutics, Inc.\DE's Change in Account Payables (Yearly) stood at -$426,000 in 2020, then skyrocketed by 488.50% to $1.7 million in 2021, then spiked by 596.31% to $11.5 million in 2022, then slumped by 204.48% to -$12.0 million in 2023, then spiked by 99.39% to -$73,000 in 2024.